The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma
Dai Chihara(The University of Texas MD Anderson Cancer Center), Yasuhiro Oki(Unknown), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), Chitra Hosing(The University of Texas MD Anderson Cancer Center), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), R. Eric Davis(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Michelle A. Fanale(Pfizer (United States)), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), Michael Wang(St. Joseph Health System), Francesco Turturro(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(Delaware Division of Libraries), Mansoor Noorani(The University of Texas MD Anderson Cancer Center), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center)
Cited by 118
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
|The Journal of Experimental Medicine|2001|1.1k